Tani Hideki, Komoda Yasumasa, Matsuo Eiko, Suzuki Kensuke, Hamamoto Itsuki, Yamashita Tetsuo, Moriishi Kohji, Fujiyama Kazuhito, Kanto Tatsuya, Hayashi Norio, Owsianka Ania, Patel Arvind H, Whitt Michael A, Matsuura Yoshiharu
Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamada-oka, Suita, Osaka 565-0871, Japan.
J Virol. 2007 Aug;81(16):8601-12. doi: 10.1128/JVI.00608-07. Epub 2007 Jun 6.
Although in vitro replication of the hepatitis C virus (HCV) JFH1 clone of genotype 2a (HCVcc) has been developed, a robust cell culture system for the 1a and 1b genotypes, which are the most prevalent viruses in the world and resistant to interferon therapy, has not yet been established. As a surrogate virus system, pseudotype viruses transiently bearing HCV envelope proteins based on the vesicular stomatitis virus (VSV) and retrovirus have been developed. Here, we have developed a replication-competent recombinant VSV with a genome encoding unmodified HCV E1 and E2 proteins in place of the VSV envelope protein (HCVrv) in human cell lines. HCVrv and a pseudotype VSV bearing the unmodified HCV envelope proteins (HCVpv) generated in 293T or Huh7 cells exhibited high infectivity in Huh7 cells. Generation of infectious HCVrv was limited in some cell lines examined. Furthermore, HCVrv but not HCVpv was able to propagate and form foci in Huh7 cells. The infection of Huh7 cells with HCVpv and HCVrv was neutralized by anti-hCD81 and anti-E2 antibodies and by sera from chronic HCV patients. The infectivity of HCVrv was inhibited by an endoplasmic reticulum alpha-glucosidase inhibitor, N-(n-nonyl) deoxynojirimycin (Nn-DNJ), but not by a Golgi mannosidase inhibitor, deoxymannojirimycin. Focus formation of HCVrv in Huh7 cells was impaired by Nn-DNJ treatment. These results indicate that the HCVrv developed in this study can be used to study HCV envelope proteins with respect to not only the biological functions in the entry process but also their maturation step.
尽管已经开发出了2a基因型丙型肝炎病毒(HCV)JFH1克隆的体外复制系统(HCVcc),但对于1a和1b基因型(这两种基因型是世界上最普遍的病毒且对干扰素治疗耐药),尚未建立起强大的细胞培养系统。作为替代病毒系统,基于水泡性口炎病毒(VSV)和逆转录病毒的瞬时携带HCV包膜蛋白的假型病毒已被开发出来。在此,我们开发了一种具有复制能力的重组VSV,其基因组编码未修饰的HCV E1和E2蛋白以取代人细胞系中的VSV包膜蛋白(HCVrv)。在293T或Huh7细胞中产生的携带未修饰HCV包膜蛋白的HCVrv和假型VSV(HCVpv)在Huh7细胞中表现出高感染性。在所检测的一些细胞系中,感染性HCVrv的产生受到限制。此外,HCVrv而非HCVpv能够在Huh7细胞中增殖并形成病灶。抗hCD81和抗E2抗体以及慢性HCV患者的血清可中和HCVpv和HCVrv对Huh7细胞的感染。内质网α-葡萄糖苷酶抑制剂N-(正壬基)脱氧野尻霉素(Nn-DNJ)可抑制HCVrv的感染性,但高尔基体甘露糖苷酶抑制剂脱氧甘露野尻霉素则不能。Nn-DNJ处理会损害HCVrv在Huh7细胞中的病灶形成。这些结果表明,本研究中开发的HCVrv不仅可用于研究HCV包膜蛋白在进入过程中的生物学功能,还可用于研究其成熟步骤。